Robert Zeillinger - Gynecology

Author Information

Robert Zeillinger is a prominent researcher affiliated with the Molecular Oncology Group, Department of Obstetrics and Gynecology at the Comprehensive Cancer Center - Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria. His work primarily focuses on gynecologic oncology, specifically ovarian cancer.

Research Contributions

Robert Zeillinger has made significant contributions to the field of gynecologic oncology. His research predominantly revolves around the early detection and prognostic evaluation of ovarian cancer through the use of biomarkers. He has been involved in multiple studies that explore the use of protein signatures, autoantibody blood tests, and circulating tumor cells to improve diagnostic accuracy and patient outcomes. His work also extends to non-small cell lung cancer, demonstrating his versatility and expertise in oncology.

Aliases

Robert Zeillinger is also known by the aliases R Zeillinger and R. Zeillinger.

Publication and Citation Metrics

Metric	Value
Total Papers	362
Total Citations	10,971
H-index	58

Publications:

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study

DOI: 10.3390/cancers14071780

Year: 2022

Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial

DOI: 10.1186/s12885-021-08682-y

Year: 2021

266 Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial

DOI: 10.1136/ijgc-2021-esgo.371

Year: 2021

BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer

DOI: 10.3390/genes12070969

Year: 2021

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium

DOI: 10.3390/cancers13235865

Year: 2021

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium

DOI: 10.3390/cancers13112613

Year: 2021

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer

DOI: 10.3390/cancers14010004

Year: 2021

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer

DOI: 10.3390/jpm11111225

Year: 2021

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer

DOI: 10.1007/s10637-021-01181-8

Year: 2021

tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression

DOI: 10.3390/cancers14010024

Year: 2021

What Conditions Are Associated with Connective Tissue Disorders in Gynecology?

What is Multimodal Anesthesia?

Are There Any Risks Associated with Urethral Swabs?

What Are the Signs of an Irregular Menstrual Cycle?

Why is Partner Involvement Important in Gynecology?

What are the Consequences of Folic Acid Deficiency?

What Should One Know About Sexual Function and Disorders?

What are Modifiers and When to Use Them?

How Can Health Systems Address Barriers to Care?

What Makes Kaiser Permanente's Gynecology Services Unique?

Partnered Content Networks

Relevant Topics